This report provides an overview of the toxicology pipeline landscape.
The report provides comprehensive information on the therapeutics under
development and key players involved in therapeutic development for
Chemotherapy Induced Nausea and Vomiting, Chemotherapy Induced
Neutropenia, Chemotherapy Induced Anemia, Chemotherapy Induced
Peripheral Neuropathy and features dormant and discontinued projects.

Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting
that results specifically from treatment with chemotherapy drugs. There
are a total of 28 products in development for this indication, by 20
companies. Key companies operating in this pipeline space include
Helsinn, Luxena Pharmaceuticals, Aphios, Nemus Bioscience and Tesaro.

The dominant molecular targets vary across each of the four pipelines.
In CINV and CIPN, there is a relatively diverse range of targets which
are being studied. The 5-hydroxytryptamine receptor 3 and substance P
receptors are most commonly being studied in CINV, as are the
cannabinoid receptors 1 and 2. There is some overlap between this and
the CIPN pipeline, with cannabinoid receptors being present amongst the
relatively diverse range of targets in development, although with the
glutamate ionotropic receptor NMDA-type being the most-frequently
selected target.

In chemotherapy-induced neutropenia, on the other hand, the granulocyte
colony stimulating factor receptor is overwhelmingly the target of
choice, accounting for virtually the entire pipeline. Similarly, the
erythropoietin receptor makes up the majority of the
chemotherapy-induced anemia pipeline. This reflects the relatively
focused nature of R&D within these two indications.